Updates are available Correction dated 2023-05-26
Click to view Correction: https://doi.org/10.1038/s41408-023-00856-0
-
Authors
Fonseca, Rodrigo http://orcid.org/0000-0001-7130-0340
Arribas, Mariano http://orcid.org/0000-0003-1859-7098
Wiedmeier-Nutor, Julia E.
Kusne, Yael N.
González Vélez, Miguel
Kosiorek, Heidi E.
Butterfield, Richard J.
Kirsch, Ilan R.
Mikhael, Joseph R. http://orcid.org/0000-0001-9670-2864
Stewart, A. Keith
Reeder, Craig http://orcid.org/0000-0002-7158-0669
Larsen, Jeremy
Bergsagel, P. Leif http://orcid.org/0000-0003-1523-7388
Fonseca, Rafael http://orcid.org/0000-0002-5938-3769
- License Information
-
More Information
Article History
Received: 7 October 2022
Revised: 26 January 2023
Accepted: 30 January 2023
First Online: 6 March 2023
Change Date: 26 May 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-023-00856-0
Competing interests
: JRM: has served as a consultant for Amgen, BMS, Janssen, Karyopharm and Sanofi. IRK is a full time employee of Adaptive Biotechnologies. AKS: has served as a consultant for Skyline, Tempus; also has a patent for cereblon as a biomarker issued and is found of a company called PIKSci Inc. PLB: has served as a consultant for Pfizer, Novartis, GSK, Janssen and Oncopeptides. RF: has served as a consultant for AbbVie, Amgen, Bayer, BMS/Celgene, GSK, H3 Therapeutics, Janssen, Juno, Karyopharm, Kite, Merck, Novartis, Oncopeptides, Oncotracker, Pfizer, Pharmacyclics, Regeneron, Sanofi, Takeda; and has served as an advisory board member for Adaptive Biotechnologies, Caris Life Sciences and OncoMyx. No disclosures were reported by the other authors.
